• Mashup Score: 0

    In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegene rative disease Clene’s nanotechnological approach was recently recognized by the NINDS of NIH with a substantial grant to conduct an Expanded Access Protocol in ALS with CNM-Au8(R) Clene aims to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024 October 2023 has

    Tweet Tweets with this article
    • Clene (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS https://t.co/BPaITsXNAW

  • Mashup Score: 1

    Skip to content About NORD NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 330 patient organization…

    Tweet Tweets with this article
    • Dear @RareDiseases @CPathInstitute I love what I just saw to educate https://t.co/nMmm1BU1OR ... but pls offer some citations every time you quote yrs it takes to develop a drug or $ required, etc. These #s become repeated & exaggerated w/o some mooring in facts. Tx. #NORDSummit